FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.

被引：0
|
作者：
Lakins, Matthew A. [1 ]
Munoz-Olaya, Jose [1 ]
Veyssier, Christel [1 ]
Jones, Daniel [1 ]
Goodman, Emma [1 ]
Kaka, Quincy [1 ]
Ofoedu, Jennifer [1 ]
Hughes, Robert [1 ]
Gliddon, Daniel [1 ]
Morrow, Michelle [1 ]
Brewis, Neil [1 ]
机构：
[1] F Star Therapeut, Cambridge, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1864
引用
收藏
页数：2
相关论文
共 29 条
  • [21] HK010, a novel anti-PDL1 x CD137 bispecific antibody, exhibits potent anti-tumor immunity and low toxicity
    Li, Liangwei
    Liu, Wenting
    Shen, Guodong
    Zhang, Dayan
    Zhou, Weiming
    Wang, Fengrong
    Zeng, Xiaoli
    Huang, Yang
    Cheng, Liansheng
    CANCER RESEARCH, 2023, 83 (07)
  • [22] FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
    Kraman, Matthew
    Faroudi, Mustapha
    Allen, Natalie L.
    Kmiecik, Katarzyna
    Gliddon, Daniel
    Seal, Claire
    Koers, Alexander
    Wydro, Mateusz M.
    Batey, Sarah
    Winnewisser, Julia
    Young, Lesley
    Tuna, Mihriban
    Doody, Jacqueline
    Morrow, Michelle
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3333 - 3344
  • [23] CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial
    Montagne, Janelle M.
    Mitchell, Jacob T.
    Tandurella, Joseph A.
    Christenson, Eric S.
    Danilova, Ludmila, V
    Deshpande, Atul
    Loth, Melanie
    Sidiropoulos, Dimitrios N.
    Davis-Marcisak, Emily
    Bergman, Daniel R.
    Zhu, Qingfeng
    Wang, Hao
    Kagohara, Luciane T.
    Engle, Logan L.
    Green, Benjamin F.
    Favorov, Alexander, V
    Ho, Won Jin
    Lim, Su Jin
    Zhang, Rui
    Li, Pan
    Gai, Jessica
    Mo, Guanglan
    Mitchell, Sarah
    Wang, Rulin
    Vaghasia, Ajay
    Hou, Wenpin
    Xu, Yao
    Zimmerman, Jacquelyn W.
    Elisseeff, Jennifer H.
    Yegnasubramanian, Srinivasan
    Anders, Robert A.
    Jaffee, Elizabeth M.
    Zheng, Lei
    Fertig, Elana J.
    ISCIENCE, 2025, 28 (01)
  • [24] Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies
    Barve, Minal A.
    Johanns, Tanner Michael
    Mettu, Niharika B.
    Rosen, Seth D.
    Edenfield, William Jeffery
    Gutierrez, Martin
    Giorlando, Aime
    Schuetz, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1
    Ramaswamy, Madhu
    Kim, Taeil
    Jones, Des C.
    Ghadially, Hormas
    Mahmoud, Tamer, I
    Garcia, Andrew
    Browne, Gareth
    Zenonos, Zenon
    Puplampu-Dove, Yvonne
    Riggs, Jeffrey M.
    Bhat, Geetha K.
    Herbst, Ronald
    Schofield, Darren J.
    Carlesso, Gianluca
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (02) : 200 - 214
  • [26] MCLA-145, AN ANTI CD137xPD-L1 BISPECIFIC ANTIBODY, INDUCES T CELL ACTIVATION AND PROLIFERATION IN EX VIVO MODELS OF HEPATOCELLULAR CARCINOMA
    Desai, Jyaysi
    Noordam, Lissane
    Boor, Patrick
    Bouzid, Rachid
    Mittag, Diana
    Tacken, Paul
    van Bueren, Jeroen Lammerts
    Guijen, Cecile
    Kwekkeboom, Jaap
    Sprengers, Dave
    Buschow, Sonja
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A920 - A920
  • [27] FS118, A TETRAVALENT BISPECIFIC ANTIBODY TARGETING LAG-3 AND PD-L1, INDUCES LAG-3 SHEDDING RESULTING IN RECEPTOR DOWNREGULATION BY T CELLS VIA A NOVEL MECHANISM OF ACTION
    Morrow, Michelle
    Faroudi, Mustapha
    Chakraborty, Krishnendu
    Liao, Wenjia
    Winnewisser, Julia
    Seal, Claire
    Gliddon, Daniel
    Brewis, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A428 - A429
  • [28] Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses
    Kraman, Matthew
    Fosh, Natalie
    Kmiecik, Katarzyna
    Everett, Katy
    Zimarino, Carlo
    Faroudi, Mustapha
    Wydro, Mateusz
    Koers, Alexander
    Young, Lesley
    Gliddon, Daniel
    Morrow, Michelle
    Doody, Jacqueline
    Tuna, Mihriban
    Brewis, Neil
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces T-cell activation with the potential to drive potent anti-tumour immune responses
    Kraman, Matthew
    Fosh, Natalie
    Kmiecik, Katarzyna
    Everett, Katy
    Zimarino, Carlo
    Faroudi, Mustapha
    Wydro, Mateusz
    Koers, Alexander
    Young, Lesley
    Morrow, Michelle
    Doody, Jacqueline
    Tuna, Mihriban
    Brewis, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
123